Bioheart, Inc.'s President / CEO Mike Tomas appointed to workforce Florida board of directors by Governor Rick Scott
SUNRISE, FL--(Marketwired - August 14, 2013) - Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors. Workforce Florida is charged with overseeing the state's workforce system and developing strategies that will improve the state's business environment while supporting its economy (www.EmployFlorida.com).
"Governor Scott's appointments to our Board of Directors are reflective of Florida's strategic focus on growing talent and jobs in dynamic industries targeted for their current and future economic impact," said Chris Hart, IV, President and CEO of Workforce Florida. "We look forward to the contributions of these leaders to our collaborative efforts with workforce, education and economic development partners in supporting and strengthening Florida's businesses and families."
Mike Tomas is CEO of Bioheart, Inc. and President of the ASTRI Group, an early-stage private equity investment company providing capital, business development and strategic marketing support to emerging private companies. He is considered an experienced marketer and operating executive for IT/Communications and Biotech/Life Sciences private equity and venture groups/portfolio companies. Tomas has spent nearly 25 years driving the evolution of pioneering technologies in the U.S. and Mexico in leadership roles. Tomas is the current chairman of Florida International University's Global Entrepreneurship Center, an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner plus other entrepreneurial awards.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.